Child-Pugh score and immunotherapy eligibility — why the liver decides before the cancer does

No. Most people diagnosed with liver cancer in India are not candidates for checkpoint inhibitor immunotherapy. Some are found early enough that surgery, ablation, transplant assessment or artery-directed treatment is the stronger option. Many more are ruled out for a different reason entirely: the liver itself is too damaged to carry systemic treatment safely.

That second group is large here. Hepatitis B, hepatitis C and alcohol-related cirrhosis are common across Telangana and Andhra Pradesh, and most liver cancers in this region are found in a liver that is already scarred. The cancer is only half the picture. The other half is how much working liver is left.

The Child-Pugh score is how that second half gets measured. It is the reason a patient can be told the tumour looks treatable and still be told immunotherapy is not on the table. Understanding the score is how you understand the decision — and, in some patients, how you change it.

At CION, immunotherapy is given as a day-care infusion — you come in, receive it, and go home the same day. Response-assessment PET-CT is coordinated at partner imaging centres. The whole pathway is set out on our immunotherapy at CION Cancer Clinics page, and the disease-specific picture on immunotherapy for liver cancer (HCC).

Point cut-offs follow the standard Child-Turcotte-Pugh classification as referenced in NCCN, ESMO and BCLC liver cancer guidance, indicative as of August 2026. Some laboratories report bilirubin and albumin in different units, and modified cut-offs exist for certain cholestatic liver diseases. Your hepatologist confirms which version applies to you.

Class boundaries are the standard ones referenced in NCCN, ESMO and BCLC liver cancer guidance, indicative as of August 2026. Guidelines are revised periodically, and your oncologist confirms which threshold applies to the specific plan being considered for you.

Four things sit behind that rule, and they compound:

• Immune-related hepatitis is a recognised side effect. Checkpoint inhibitor immunotherapy can inflame the liver. On a healthy liver that is manageable. On a cirrhotic liver with little spare capacity, the same event has far less room to be absorbed.
• The evidence base was built in Class A patients. The studies that established systemic treatment in liver cancer enrolled almost entirely Child-Pugh A patients. Outside that group, nobody can tell you what the balance of benefit and harm looks like, because it was never properly measured.
• Decompensation itself becomes the bigger threat. In Class C, ascites, encephalopathy and bleeding usually shorten life sooner than the tumour does. Treating the cancer at that point can make the liver worse without changing what is actually driving the illness.
• The score feeds the staging system. The BCLC framework used in liver cancer combines liver function, tumour extent and your performance status into one decision. Child-Pugh is the liver-function input. It is why the same tumour leads to different advice in two different people.

This is a framework, not a verdict. It includes the option of not giving anticancer treatment, which is a real and sometimes correct choice. Where the liver is failing, controlling ascites, protecting against infection and managing symptoms may do more for you than any systemic drug — and that decision belongs in a tumour board discussion, not a single consultation.

What can genuinely move the number, when the treating team works on it:

• Ascites brought under control — salt restriction and diuretics prescribed and titrated by your hepatology team can take this row from 3 points to 2, or to 1.
• Encephalopathy treated — confusion and drowsiness from liver failure are treatable, and controlled encephalopathy scores lower than uncontrolled.
• Active hepatitis B or C suppressed — antiviral treatment reduces ongoing liver injury, and bilirubin, albumin and INR can improve over months as a result.
• Alcohol stopped completely — in alcohol-related cirrhosis this is often the single largest change available, and the improvement can continue for several months.
• Nutrition and protein intake improved — albumin is a liver product, but it is also a nutrition marker, and malnutrition is common and correctable in cirrhosis.
• Hepatotoxic and unregulated preparations withdrawn — over-the-counter painkillers, some prescribed drugs, and unregulated herbal or Ayurvedic liver preparations can all raise bilirubin. Tell your oncologist everything you are taking, including anything traditional. The aim is disclosure so the team can check for interactions, not judgement about what you take.

The reverse is also true, and it matters. Infection, a gastrointestinal bleed, dehydration or a kidney injury can push the score up sharply for a few weeks and then settle. A single set of blood tests taken during an acute illness is a poor basis for a permanent decision. If you were scored while unwell, it is reasonable to ask when you will be re-scored.

In practice, a hepatologist and an oncologist work on the liver together for several weeks, then re-check. Some patients move from Class B into Class A, and the conversation about systemic treatment reopens. Others do not. Neither outcome is a moral verdict on how hard you tried.

Being precise about this matters, because the term is used loosely. MSI-high or dMMR status is confirmed in one of two ways: immunohistochemistry for the four mismatch-repair proteins — MLH1, PMS2, MSH2 and MSH6 — where loss of one or more indicates deficiency, or PCR or next-generation sequencing of microsatellite markers reported as MSI-high. A single unexplained result, or a report that simply says "MSI done", is not the same thing as a confirmed MSI-high result.

Where it applies also matters. MSI-high is uncommon in hepatocellular carcinoma. It is far more relevant across colorectal and other lower GI cancers, which is where universal testing is recommended — our page on immunotherapy for MSI-high colorectal cancer covers that route in detail, and MSI-high and dMMR explained covers the testing itself.

The two questions are simply different. A biomarker can make you a candidate on paper. The Child-Pugh class decides whether the liver can take it. Both have to be answered before anyone starts.

1. 1

   Liver function tests and clinical scoring

   Bilirubin, albumin and INR from a blood sample, plus an examination for ascites and encephalopathy. Those five values produce the Child-Pugh score. Nothing extra is booked or paid for.

2. 2

   Hepatitis B and C screening — routine protocol

   Hepatitis B surface antigen, hepatitis B core antibody and hepatitis C antibody are tested before immunotherapy starts, with viral load testing where a result is positive. Hepatitis B can reactivate during immune-modulating treatment, so antiviral cover is arranged with the hepatology team before the first infusion and continued alongside it. Our page on hepatitis B, hepatitis C and immunotherapy explains this in full.

3. 3

   Imaging and tumour assessment

   Cross-sectional imaging maps how far the cancer has spread and whether the portal vein is involved. Response-assessment PET-CT, where it is needed later, is coordinated at partner imaging centres rather than performed in-house.

4. 4

   Tumour board decision

   Medical, surgical and radiation oncologists review the liver function class, the tumour extent, your performance status and any biomarker result together. At CION every patient is discussed this way, so no single doctor decides eligibility alone.

If your liver enzymes rise once treatment has started, that is a separate conversation with its own protocol — see raised liver enzymes during immunotherapy.

• Immunotherapy Before Surgery for MSI-High Rectal Cancer — where an MSI-high result changes the plan most dramatically, and how that route is assessed.
• Immunotherapy With a Stoma — practical answers for lower GI patients already living with a stoma when treatment is discussed.
• Immunotherapy for Ovarian Cancer: Where the Evidence Stands — a clear example of how honestly a page can say the evidence is not yet there.
• Immunotherapy at CION Cancer Clinics — the whole pathway, from eligibility to day-care infusion and follow-up.

This page explains the Child-Pugh score in general terms, for education only. It does not interpret any individual patient's reports, and it does not recommend or discuss any specific medicine. Cut-offs and class boundaries cited are indicative as of August 2026 and follow the standard Child-Turcotte-Pugh classification as referenced in NCCN, ESMO and BCLC liver cancer guidance. Immunotherapy at CION is given as a day-care infusion; response-assessment PET-CT is coordinated at partner imaging centres. Bring your reports to a consultation for a doctor's assessment.

Liver disease and liver cancer travel together in this region

Hepatitis B, hepatitis C and alcohol-related cirrhosis are common across Telangana and Andhra Pradesh, and most liver cancers here are found in a liver that is already scarred. Our oncologists explain every report in plain Telugu or English, with time to ask questions.